What Happened

Aardvark Therapeutics reported Q2 2026 financial results with $73.9M in cash, projecting funding through late 2027. The company terminated Phase 3 HERO and OLE trials for ARD-101 in June 2026 and is analyzing unblinded data to determine next steps for the PWS program.

Who Is Affected

Metabolic disease biopharma competitors and PWS-focused healthcare providers should monitor Aardvark's FDA negotiations. The company's $14.4M net loss indicates continued R&D commitment despite financial pressures.

Market Impact

• 39 institutional investors added $AARD positions last quarter
• Median analyst price target of $6.50
• $10.5M Q2 R&D spend signals ongoing development activity

What to Watch

Key milestones include Q3 2026 data analysis completion and FDA hold resolution. The cash runway through late 2027 creates urgency for commercial partnerships.

Related coverage

• FDA approves Revolution Medicines' daraxonrasib for advanced pancreatic cancer
• FDA Accepts NDA for Apnimed's Sleep Apnea Pill AD109
• Longeveron's Laromestrocel reduces neuroinflammation in Alzheimer's patients
• 6-Month RR-TB Trial as a Pragmatic Design Blueprint